News Two more biotechs, Metsera and Maze, cross IPO finish line Metsera and Maze Therapeutics have become the second and third biotechs to complete an IPO on the Nasdaq this year.
News Ascentage raises $126m in first biotech IPO of 2025 China's Ascentage completes the first US biotech IPO of 2025, raising $126m for its pipeline of small-molecule cancer drugs.
News AMR biotech BioVersys plans to float on Swiss stock exchange BioVersys has filed to list on the Swiss Stock Exchange, hoping to raise CHF80m for its novel antibacterial candidates.
News Two more biotechs join IPO waiting list Odyssey and Sionna have filed to carry out IPOs on the Nasdaq, following after Metsera and Maze which filed earlier in January.
News Nine-month-old obesity player Metsera files an IPO Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs.
News Nasdaq debutante Septerna swells its IPO to $331m Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount raised topping $331 million.
News NHS trust rolls out digital health tool for kidney disease An NHS trust in England is starting a pilot study of a digital health platform that promises to improve the care of people with kidney disease.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
